Pneumonia (Nov 2024)

Streptococcus pneumoniae serotype distribution in Bangladeshi under-fives with community-acquired pneumonia pre-10-valent pneumococcal conjugate vaccination

  • Stefan M. T. Vestjens,
  • Suzan P. van Mens,
  • Bob Meek,
  • Tariq A. Lalmahomed,
  • Ben de Jong,
  • Doli Goswami,
  • Bart J. M. Vlaminckx,
  • Dilruba Ahmed,
  • Bartelt M. de Jongh,
  • Hubert P. Endtz,
  • W. Abdullah Brooks,
  • Ger T. Rijkers

DOI
https://doi.org/10.1186/s41479-024-00152-w
Journal volume & issue
Vol. 16, no. 1
pp. 1 – 9

Abstract

Read online

Abstract Background Streptococcus pneumoniae is the most frequent causative pathogen of bacterial pneumonia in children worldwide. Bangladesh introduced the 10-valent pneumococcal conjugate vaccine (PCV10) in their national immunization program for infants in 2015. We assessed its potential coverage in under-fives with community-acquired pneumonia (CAP) in the years before PCV10 was introduced. Methods A total of 1502 childhood pneumonia cases (< 5 year olds living in the urban section Kamalapur, Dhaka) were enrolled between 2011 and 2013. Acute phase and late (convalescent) serum samples were collected from 1380 cases. Serotype-specific pneumococcal antibody concentrations were measured using a 25-plex immunoassay panel. Pneumococcal CAP was diagnosed based on a serotype-specific pneumococcal antibody response. Results S. pneumoniae was serologically identified as causative pathogen in 406/1380 (29%) cases. The five most prevalent serotypes were (in descending order) 11A, 22F, 3, 2 and 19F. Based on the percentage of pneumonia cases associated with PCV10 vaccine types, the potential PCV10 coverage was 29% (116/406). Conclusions In almost a third of the studied cases S. pneumoniae was identified as a causative pathogen. Because of the characteristics of the immunoassay, this might well be a gross underestimation. Nevertheless, the potential PCV10-coverage was low. Given the high serotype diversity, the region might benefit greatly from a higher-coverage PCV or recombinant protein vaccine.

Keywords